Previous studies demonstrated that abnormal expression of IRF4 identified as a diagnostic and prognostic marker was associated with various hematological malignancies such as Chronic lymphocytic leukemia (CLL), T-cell leukemia/lymphoma and Multiple myeloma (10–12). The gene discussed is IRF4; the disease is B-cell chronic lymphocytic leukemia.